10/815,119

## Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

## Listing of Claims:

- 1.-21. (Cancelled)
- (Previously Presented) A method of treating vasospasm in a subject needing such treatment comprising the step of:

topically applying to a region of the subject's tissue requiring treatment of vasospasm an effective amount of a semi-solid composition, the composition comprising:

a vasoactive prostaglandin;

- a penetration enhancer selected from the group consisting of an alkyl-N-substituted amino) alkanoate, an alkyl-2-(N,N-disubstituted amino) alkanoate, an (N,N-disubstituted amino) alkanoate, an (N,N-disubstituted amino) alkanoal alkanoate, a pharmaceutically acceptable salt thereof and a mixture thereof; a polymer thickener consisting of shear-thinning polysaccharide gum selected from a guar gum, and a modified guar gum:
- a lipophilic component that is selected from the group consisting of an aliphatic  $C_1$  to  $C_8$  alcohol, an aliphatic  $C_8$  to  $C_{50}$  ester, a liquid polyol and a mixture thereof; water and
- a buffer system that provides a buffered pH value for said composition in the range of about 3 to about 7.4:

wherein application of the semi-solid composition produces an increase in blood flow through the region of vasospasm within thirty minutes of the application.

- 23. (Original) The method of claim 22 wherein the tissue is skin.
- 24. (Withdrawn) The method of claim 22 wherein the tissue is vascular extima.
- 25. (Original) The method of claim 22 wherein the vasoactive prostaglandin is selected from the group consisting of prostaglandin E<sub>1</sub>, prostaglandin E<sub>2</sub>, a pharmaceutically acceptable salt thereof, a lower alkyl ester thereof and a mixture thereof.
- (Cancelled)
- 27. (Original) The method of claim 22 wherein the penetration enhancer is dodecyl 2-(N,N-dimethylamino)-propionate or a pharmaceutically acceptable salt thereof.
- (Original) The method of claim 22 wherein the lipophilic component comprises at least one aliphatic C<sub>8</sub> to C<sub>10</sub> ester.
- 29. 64. (Cancelled)